Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice

“Although the FDA updated the [capecitabine] label this month, last week the NCCN updated 3 of their guidelines—colon cancer, rectal cancer, and small bowel adenocarcinoma—to incorporate the same language regarding DPYD testing. So, this is now truly something the community must embed and implement in existing care plans.” – Houda Hachad, PharmD, M.Res

Watch & read Houda’s interview with the Journal of Clinical Pathways regarding the clinical implications of the FDA’s capecitabine boxed warning in oncology: https://www.hmpgloballearningnetwork.com/site/jcp/videos/clinical-implications-fdas-capecitabine-boxed-warning-integrating-dpyd-testing